Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
Release Notes Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: BNC003
MIFTS: 53

Bone Cancer

Categories: Bone diseases, Cancer diseases, Rare diseases
Data Licensing
For inquiries, contact:
[email protected]
Genes Variations Tissues Related diseases Publications Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Bone Cancer

About this section

MalaCards integrated aliases for Bone Cancer:

Name: Bone Cancer 11 41 14
Malignant Bone Neoplasm 11 16 71
Bone Carcinoma 11 14 71
Bone Neoplasms 75 43 71
Bone Neoplasm 11 16
Malignant Neoplasm of Bone 11
Malignant Osseous Tumor 11
Malignant Bone Tumour 11
Osteosarcoma of Bone 71
Osteogenic Neoplasm 71
Ca - Bone Cancer 11
Neoplasm of Bone 11
Osseous Tumor 11
Bone Tumour 11

Classifications:

MalaCards categories:
Global: Cancer diseases Rare diseases
Anatomical: Bone diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 11 DOID:184 DOID:2762
MeSH 43 D001859
NCIt 49 C36082 C9343
SNOMED-CT 68 126537000 269568000
UMLS 71 C0005967 C0279530 C0585442 more
Sources

Summaries for Bone Cancer

About this section

MedlinePlus: 41 Cancer that starts in a bone is uncommon. Cancer that has spread to the bone from another part of the body is more common. There are three types of bone cancer: Osteosarcoma - occurs most often between ages 10 and 19. It is more common in the knee and upper arm. Chondrosarcoma - starts in cartilage, usually after age 40 Ewing's sarcoma - occurs most often in children and teens under 19. It is more common in boys than girls. The most common symptom of bone cancer is pain. Other symptoms vary, depending on the location and size of the cancer. Surgery is often the main treatment for bone cancer. Other treatments may include amputation, chemotherapy, and radiation therapy. Because bone cancer can come back after treatment, regular follow-up visits are important. NIH: National Cancer Institute

MalaCards based summary: Bone Cancer, also known as malignant bone neoplasm, is related to bone marrow cancer and osteogenic sarcoma, and has symptoms including back pain, sciatica and muscle cramp. An important gene associated with Bone Cancer is MIR199A1 (MicroRNA 199a-1), and among its related pathways/superpathways are Colorectal Cancer Metastasis and DNA IR-double strand breaks and cellular response via ATM. The drugs Denosumab and Pregabalin have been mentioned in the context of this disorder. Affiliated tissues include bone, prostate and breast, and related phenotype is no phenotypic analysis.

Disease Ontology 11 Bone cancer: A connective tissue cancer that is located in bone and is characterized by uncontrolled cellular proliferation that destroys normal bone tissue.

Bone carcinoma: A bone cancer that has material basis in abnormally proliferating cells derives from epithelial cells.

Wikipedia: 75 A bone tumor is an abnormal growth of tissue in bone, traditionally classified as noncancerous (benign)... more...
Sources

Related Diseases for Bone Cancer

About this section

Diseases in the Bone Cancer family:

Primary Bone Cancer

Diseases related to Bone Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 614)
# Related Disease Score Top Affiliating Genes
1 bone marrow cancer 33.0 TP53 MIR9-1 MIR335 MIR21 MIR199A1 MIR17
2 osteogenic sarcoma 32.6 TP53 MMP9 MIR199A1 CDKN2A CASP3
3 bone squamous cell carcinoma 32.4 TP53 MMP9 EGFR CDKN2A
4 bone sarcoma 32.3 TP53 MIR9-1 MIR485 MIR335 MIR199A1 MIR17
5 li-fraumeni syndrome 32.2 TP53 H2AC18 EGFR CDKN2A
6 ewing sarcoma 31.4 TP53 MIR9-1 MIR199A1 H2AC18 CDKN2A CASP3
7 bone disease 31.3 MMP9 MIR9-1 MIR21 MIR199A1 MIR17 MIR126
8 myeloma, multiple 31.1 TP53 MIR9-1 MIR335 MIR32 MIR21 MIR199A1
9 lung cancer 31.0 TP53 MMP9 MIR9-1 MIR485 MIR335 MIR32
10 chordoma 30.8 TP53 MMP9 EGFR CDKN2A
11 bone inflammation disease 30.7 MMP9 MIR9-1 MIR335 MIR21 MIR199A1 MIR17
12 brain cancer 30.7 TP53 MIR9-1 MIR21 MIR199A1 MIR17 MIR126
13 hepatocellular carcinoma 30.7 TP53 MMP9 MIR9-1 MIR877 MIR485 MIR335
14 prostate cancer 30.7 TP53 MMP9 MIR335 MIR32 MIR21 MIR199A1
15 neurofibroma 30.7 TP53 EGFR CDKN2A
16 rectum cancer 30.6 TP53 MIR21 MIR17 MIR126 H2AC18 EGFR
17 rectal benign neoplasm 30.5 TP53 MIR17 EGFR
18 mesothelioma, malignant 30.5 MIR32 MIR17 MIR126 H2AC18 CDKN2A
19 gastrointestinal system disease 30.5 MIR9-1 MIR485 MIR335 MIR21 MIR199A1 MIR183
20 renal cell carcinoma, nonpapillary 30.4 TP53 MMP9 MIR9-1 MIR335 MIR21 MIR199A1
21 ovarian cancer 30.4 TP53 MMP9 MIR9-1 MIR627 MIR485 MIR335
22 meningioma, familial 30.4 TP53 MMP9 MIR335 H2AC18 EGFR CDKN2A
23 neuroblastoma 30.4 TP53 MMP9 MIR21 MIR17 EGFR CDKN2A
24 squamous cell carcinoma 30.4 TP53 MMP9 MIR199A1 EGFR CDKN2A CASP3
25 myxofibrosarcoma 30.4 TP53 H2AC18 CDKN2A
26 connective tissue cancer 30.4 TP53 MIR9-1 MIR485 MIR335 MIR32 MIR21
27 lip and oral cavity cancer 30.4 TP53 MMP9 MIR21 EGFR CDKN2A CASP3
28 parkinson disease, late-onset 30.4 MIR9-1 MIR433 MIR335 MIR21 MIR126 H2AC18
29 hematologic cancer 30.4 MIR9-1 MIR335 MIR21 MIR199A1 MIR17 MIR151A
30 skin carcinoma 30.4 TP53 MIR21 MIR199A1 H2AC18 EGFR CDKN2A
31 diabetes mellitus 30.4 TP53 MMP9 MIR21 MIR17 MIR126 EGFR
32 microvascular complications of diabetes 5 30.4 MIR21 MIR199A1 MIR17 MIR126 H2AC18
33 leukemia, chronic myeloid 30.4 TP53 MIR9-1 MIR199A1 MIR17 MIR151A MIR126
34 head and neck cancer 30.4 TP53 MMP9 MIR9-1 MIR876 MIR485 MIR335
35 peripheral nervous system disease 30.4 TP53 MMP9 MIR9-1 MIR485 MIR335 MIR21
36 esophageal cancer 30.4 TP53 MMP9 MIR9-1 MIR485 MIR21 MIR199A1
37 mantle cell lymphoma 30.4 TP53 MIR9-1 MIR17 H2AC18 EGFR CDKN2A
38 breast adenocarcinoma 30.4 TP53 MMP9 H2AC18 EGFR CDKN2A CASP3
39 bladder cancer 30.4 TP53 MMP9 MIR21 MIR199A1 MIR17 H2AC18
40 body mass index quantitative trait locus 11 30.4 TP53 MMP9 MIR9-1 MIR335 MIR21 MIR199A1
41 hemangioma 30.4 TP53 MMP9 EGFR CDKN2A
42 type 2 diabetes mellitus 30.3 TP53 MMP9 MIR9-1 MIR335 MIR21 MIR199A1
43 pancreatic cancer 30.3 TP53 MMP9 MIR32 MIR21 MIR199A1 MIR17
44 gastric cancer 30.3 TP53 MMP9 MIR9-1 MIR21 MIR199A1 MIR17
45 basal cell carcinoma 30.3 TP53 MMP9 H2AC18 EGFR CDKN2A
46 estrogen-receptor positive breast cancer 30.3 TP53 H2AC18 EGFR
47 lymphoma, hodgkin, classic 30.3 TP53 MIR9-1 MIR21 H2AC18
48 suppressor of tumorigenicity 3 30.3 TP53 CDKN2A
49 malignant peripheral nerve sheath tumor 30.3 TP53 EGFR CDKN2A
50 carcinosarcoma 30.2 TP53 EGFR CDKN2A

Graphical network of the top 20 diseases related to Bone Cancer:



Diseases related to Bone Cancer
Sources

Symptoms & Phenotypes for Bone Cancer

About this section

UMLS symptoms related to Bone Cancer:


back pain; sciatica; muscle cramp

MGI Mouse Phenotypes related to Bone Cancer:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 no phenotypic analysis MP:0003012 9.17 CASP3 CDKN2A EGFR MIR126 MIR199A1 MIR9-1
Sources

Drugs & Therapeutics for Bone Cancer

About this section

Drugs for Bone Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 175)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Denosumab Approved Phase 4 615258-40-7
2
Pregabalin Approved, Investigational Phase 4 148553-50-8 5486971
3
Cholecalciferol Approved, Nutraceutical, Vet_approved Phase 4 67-97-0, 1406-16-2 5280795 10883523
4 Vitamins Phase 4
5 Calciferol Phase 4
6 Diphosphonates Phase 4
7 Immunoglobulins Phase 4
8 Antibodies Phase 4
9 Immunoglobulins, Intravenous Phase 4
10 Immunoglobulin G Phase 4
11 Antibodies, Monoclonal Phase 4
12 Hormones Phase 4
13 Calcium, Dietary Phase 4
14 Anti-Anxiety Agents Phase 4
15 Psychotropic Drugs Phase 4
16 Anticonvulsants Phase 4
17 calcium channel blockers Phase 4
18
Calcium Nutraceutical Phase 4 7440-70-2 271
19
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
20
Cefazolin Approved Phase 3 25953-19-9 33255
21
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3 3680
22
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 3003 5743
23
Captopril Approved Phase 3 62571-86-2 44093
24
Phenol Approved, Experimental Phase 3 108-95-2 996
25
Ethanol Approved Phase 3 64-17-5 702
26
Picropodophyllin Approved, Investigational Phase 3 518-28-5, 477-47-4 10607 72435
27
Daunorubicin Approved Phase 3 20830-81-3 30323
28
Mechlorethamine Approved, Investigational Phase 3 51-75-2 4033
29 Grape Approved Phase 3
30 Cranberry Approved, Investigational Phase 3
31
Ibandronate Approved, Investigational Phase 3 114084-78-5 60852
32
Molybdenum Approved Phase 3 7439-98-7 185498
33
Etanercept Approved, Investigational Phase 2, Phase 3 185243-69-0
34
Tranexamic acid Approved Phase 3 1197-18-8 5526
35
Tanezumab Investigational Phase 3 880266-57-9
36
Camptothecin Experimental Phase 3 7689-03-4 24360
37 Anesthetics, Intravenous Phase 3
38 Anesthetics, General Phase 3
39 Narcotics Phase 3
40 Cephalosporins Phase 3
41 Antitubercular Agents Phase 3
42 Analgesics, Opioid Phase 3
43 Hormone Antagonists Phase 3
44 Methylene diphosphonate Phase 3
45 Endothelial Growth Factors Phase 2, Phase 3
46 Mitogens Phase 2, Phase 3
47 Antineoplastic Agents, Hormonal Phase 3
48 HIV Protease Inhibitors Phase 3
49 Antiemetics Phase 3
50 glucocorticoids Phase 3

Interventional clinical trials:

(show top 50) (show all 244)
# Name Status NCT ID Phase Drugs
1 Zoledronic Acid Combined Radiotherapy for Bone Metastasis of Non-small Cell Lung Cancer: A Non-inferiority, Randomized, Open, Parallel and Controlled Prospective Clinical Study Unknown status NCT02480634 Phase 4 Zoledronic acid
2 The Efficacy and Safety of PEG-rhG-CSF in Neutropenia After Chemotherapy Unknown status NCT02905916 Phase 4 PEG-rhG-CSF
3 An Open Label Study of the Efficacy, Safety, and Pharmacoeconomics of Oral Ibandronate (Bondronat 50 mg) in Treatment of Metastatic Bone Disease Completed NCT02564107 Phase 4 Ibandronate
4 A Phase IV Study of Zoledronic Acid Therapy in Patients With Bone Metastases From Breast Cancer or Hormone Resistant Prostate Cancer, or Bone Involvement From Multiple Myeloma, Assessing Long-term Efficacy and Safety Completed NCT00434447 Phase 4 Zoledronic acid
5 Open-Label Study to Establish the Short Term Efficacy of Intravenous Loading-Doses of Bondronat 6 mg in Patients With Breast Cancer and Skeletal Metastases Experiencing Moderate to Severe Pain, Within 7 Days After Initiation of Treatment Completed NCT02553707 Phase 4 Ibandronate
6 An International Multicentric, Multidisciplinary Prospective and Randomized Study to Compare Minimally Invasive Reduction and Fixation Using the KyphX System and Radiopaque PMMA Cement to Medical Therapy Alone for the Treatment of Painful, Acute Osteopenic Vertebral Body Compression Fractures Completed NCT00211211 Phase 4
7 Efficacy and Safety Study of ZOMETA® in Treatment of High-level NTX Non Small Cell Lung Cancer With Bone Metastasis Completed NCT00762346 Phase 4 zometa
8 A Multi-center Observational Clinical Study of Screening of Non-small-cell Lung Cancer With Bone Metastasis and Efficacy and Safety of Those Receiving Bisphosphonates Completed NCT00765687 Phase 4 bisphosphates
9 A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid and Circulating Tumor Cell Measurements in Patients With HER2-negative Metastatic Breast Cancer Without Bone Metastasis Completed NCT01129336 Phase 4 Zoledronic acid;Standard Therapy
10 A Prospective, Single-arm Multicenter Study to Evaluate Effect of Intravenous Zoledronic Acid on Bone Metabolism Given Over 4 Months in Patients With Prostate Cancer or Breast Cancer and Bone Metastasis Completed NCT00334139 Phase 4 Zoledronic Acid
11 Effect of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastasis Completed NCT00237159 Phase 4 Zoledronic acid
12 Assessment of the Efficacy, Tolerability and Pharmaco-economic Impact of Zoledronic Acid Treatment in Prostate Cancer With Bone Metastasis Completed NCT00241111 Phase 4 zoledronic acid
13 Bioactive Glass Granules as Bone Graft Substitute in Filling Material of Bone Defects Completed NCT01304121 Phase 4
14 Long-term Safety Follow-up of Subjects With Giant Cell Tumor of Bone Treated With Denosumab in Study 20062004 Active, not recruiting NCT03301857 Phase 4 Denosumab (Cohort A)
15 An Open-label, Multi-center, Phase 4 Study of XGEVA® (Denosumab) in Chinese Adults and Skeletally Mature Adolescents With Giant Cell Tumor of the Bone Not yet recruiting NCT04586660 Phase 4 XGEVA®
16 Efficacy Evaluation of Strontium-89 Chloride for Differentiated Thyroid Cancer With Bone Metastases Not yet recruiting NCT05466812 Phase 4 Sr-89
17 A Randomized Placebo-Controlled Trial Of The Efficacy And Tolerability Of Flexibly Dosed Pregabalin In The Treatment Of Cancer-Induced Bone Pain Terminated NCT00381095 Phase 4 Pregabalin;Placebo
18 A Multi-center, Randomized, Double-blind, Comparative Study to Evaluate the Clinical Efficacy and Safety of QL1206 and Xgeva® in Patients With Bone Metastases From Solid Tumors Unknown status NCT04550949 Phase 3 QL1206;Xgeva
19 Laser Therapy Prevents Mucositis Oral in Patients Undergoing to Chemotherapy for Bone Marrow Transplantation? A Randomized Clinical Trial. Unknown status NCT02020928 Phase 3
20 18F-Fluoride PET/CT Versus 99mTc-MDP Scanning for Detecting Bone Metastases: A Randomized, Multi-Center Trial to Compare Two Bone Imaging Techniques Unknown status NCT00882609 Phase 3
21 Phase 3 Study Evaluating Fentanyl Transmucosal in the Prevention of Pain Induced by Mobilization During Radiotherapy in Patients With Bone Metastasis Unknown status NCT02426697 Phase 3 fentanyl transmucosal;Placebo
22 Clinical, Pathologic Characteristics and Its Mechansim of Denosumab Treated Giant Cell Tumor of Bone Unknown status NCT03259152 Phase 3 Denosumab
23 Biological Image Guided Antalgic Stereotactic Body Radiotherapy of Bone Metastases: a Randomized Phase II/III Trial Unknown status NCT01429493 Phase 2, Phase 3
24 Randomized, Open Label Study to Evaluate Renal Safety of Intravenous Bondronat 6 mg Infusions Over 15 Minutes Versus 60 Minutes in Patients With Metastatic Bone Disease Due to Breast Cancer Completed NCT02716792 Phase 3 Ibandronate
25 Randomized, Open Label Study to Assess the Efficacy and Safety of the Intravenous and Oral Ibandronic Acid for Improving the Performance Status of Patients With Malignant Bone Disease Secondary to Solid Tumors and Hematological Malignancies Completed NCT02561039 Phase 3 Ibandronate
26 Prophylactic Antibiotic Regimens in Tumor Surgery (PARITY): A Multi-Center International Randomized Controlled Trial Comparing Alternative Antibiotic Regimens in Patients Undergoing Tumor Resections With Endoprosthetic Replacements Completed NCT01479283 Phase 3 24-Hour Prophylactic Cefazolin* Antibiotic Regimen;5-Days Prophylactic Cefazolin* Antibiotic Regimen
27 A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF THE ANALGESIC EFFICACY AND SAFETY OF THE SUBCUTANEOUS ADMINISTRATION OF TANEZUMAB (PF-04383119) IN SUBJECTS WITH CANCER PAIN PREDOMINANTLY DUE TO BONE METASTASIS RECEIVING BACKGROUND OPIOID THERAPY Completed NCT02609828 Phase 3 Tanezumab
28 Phase III Study of Palliative Radiotherapy for Bone Metastases Comparing Single to Multiple Fractions. Completed NCT00858741 Phase 3
29 A Randomized, Open-Label, Crossover, Controlled, Multi-center Clinical Study to Assess the Diagnostic Performance and Safety of 18F-NaF-PET/CT in Bone Metastases of Malignant Tumors Compared With 99mTc⁃MDP-BS±SPECT Completed NCT05614518 Phase 3 Sodium Fluoride F-18 Injection;Technetium[99mTc] Methylenediphosphonate Injection
30 Randomized Phase 2 Study on the Relationship Between Circulating VEGF and Weekly or Every-four-week Zometa in Breast Cancer Patients With Bone Metastases Completed NCT00524849 Phase 2, Phase 3 Zoledronic acid
31 An Open Label, Single Arm, Extension Study to Evaluate the Long Term Safety of Denosumab in the Treatment of Bone Metastases in Subjects With Advanced Cancer or Multiple Myeloma Completed NCT00950911 Phase 3 amg 162
32 Dexamethasone for the Prevention of a Pain Flare After Palliative Radiotherapy for Painful Bone Metastases: a Multi-center Double-blind Placebo-controlled Randomized Study Completed NCT01669499 Phase 3 Dexamethasone acetate;Placebo
33 Prevention of Chemotherapy Induced Cardiotoxicity in Children With Bone Tumors and Acute Myeloid Leukemia Completed NCT03389724 Phase 3 Capoten®
34 Investigation of Optimal Radiotherapy Regimen and Type of Irradiation in Treatment of Painful Bone Metastasis Completed NCT00610272 Phase 3
35 A Randomized, Double-Blind, Multicenter Study of Denosumab Compared With Zoledronic Acid (Zometa) in the Treatment of Bone Metastases in Subjects With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma. Completed NCT00330759 Phase 3 Zoledronic Acid
36 A Randomized, Double-Blind, Multicenter Study of Denosumab Compared With Zoledronic Acid (Zometa®) in the Treatment of Bone Metastases in Men With Hormone-Refractory Prostate Cancer Completed NCT00321620 Phase 3 zoledronic acid
37 A Randomized, Double-Blind, Multicenter Study of Denosumab Compared With Zoledronic Acid (Zometa®) in the Treatment of Bone Metastases in Subjects With Advanced Breast Cancer Completed NCT00321464 Phase 3 Zoledronic Acid
38 A Randomized, Double-blind, Multi-centre Study to Evaluate the Fficacy and Safety of Zometa as a Treatment in Patients With Bone Metastases of Any Solid Tumors or Multiple Myeloma Completed NCT00219258 Phase 3 Zoledronic acid
39 A Randomized Phase III Double-Blind Study of Dexamethasone Versus Placebo in the Prophylaxis of Radiation-Induced Pain Flare Following Palliative Radiotherapy for Bone Metastases Completed NCT01248585 Phase 3 Dexamethasone;Placebo
40 A Randomized Trial Evaluating Rapid Delivery of Dose Escalated Hypofractionated Radiotherapy for Patients Diagnosed With Bone Metastases for Effective Palliation of Symptoms Completed NCT02163226 Phase 2, Phase 3
41 Open-Label Access Protocol of Denosumab for Subjects With Advanced Cancer Completed NCT01419717 Phase 3 Denosumab
42 Focused Ultrasound and RadioTHERapy for Noninvasive Palliative Pain Treatment in Patients With Bone Metastases Recruiting NCT04307914 Phase 3
43 Local Bisphosphonate Effect on Recurrence Rate in Extremity Giant Cell Tumor of Bone: A Prospective Randomized Controlled Trial Recruiting NCT03295981 Phase 3 Zoledronic Acid
44 Open-label Clinical Trial on the Safety and Efficacy of 18F-sodium Fluoride (NaF) PET Imaging in Patients in Need of a Standard 99mTc Bone Scintigraphy Recruiting NCT04842071 Phase 3
45 Tranexamic Acid (TXA) to Reduce Volume Of Blood Transfused In Pediatric And Young Adult Cancer Patients Undergoing Limb Salvage Procedure Of A Lower Extremity Recruiting NCT04410042 Phase 3 Tranexamic Acid
46 A Phase III Study Comparing Efficacy and Safety of LY01011 and Xgeva®(Denosumab) in Patients With Bone Metastases From Solid Tumors Recruiting NCT04859569 Phase 3 LY01011;Xgeva®
47 Randomized Phase 3 Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008) to Multiagent Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma Active, not recruiting NCT02306161 Phase 3 Cyclophosphamide;Doxorubicin;Doxorubicin Hydrochloride;Etoposide;Etoposide Phosphate;Ifosfamide;Vincristine;Vincristine Sulfate
48 A Multi-center, Randomized, Double-blind, Parallel Controlled Phase Ⅲ Clinical Study to Evaluate the Efficacy and Safety of Recombinant Human Anti RANKL Monoclonal Antibody Injection (MW032) and Denosumab (Xgeva®) in Subjects With Bone Metastases From Solid Tumors Active, not recruiting NCT04812509 Phase 3 MW032;Xgeva
49 A Multi-Center Phase III, Randomized, Open-Label Trial of Vigil (Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy) in Combination With Irinotecan and Temozolomide as a Second-Line Regimen for Ewing's Sarcoma Active, not recruiting NCT03495921 Phase 3 Irinotecan;Temozolomide
50 A Cross-over Comparison of the Diagnostic Accuracy of Technetium (99mTc) Medronate Injection Prepared With 99mTc Derived From Neutron-activation Produced 99Mo Versus the Current Reference Standard of 99mTc Derived From Fission-produced 99Mo Terminated NCT03002454 Phase 3 99mTc MDP Injection:neutron-bombardment

Search NIH Clinical Center for Bone Cancer

Inferred drug relations via UMLS 71 / NDF-RT 50 :


ZOLEDRONIC
zoledronic acid

Cochrane evidence based reviews: bone neoplasms

Sources

Genetic Tests for Bone Cancer

About this section
Sources

Anatomical Context for Bone Cancer

About this section

Organs/tissues related to Bone Cancer:

FMA: Bone
MalaCards : Bone, Prostate, Breast, Lung, Thyroid, Dorsal Root Ganglion, Kidney
Sources

Publications for Bone Cancer

About this section

Articles related to Bone Cancer:

(show top 50) (show all 3462)
# Title Authors PMID Year
1
Effects of an Exercise Intervention on Gait Function in Young Survivors of Osteosarcoma with Megaendoprosthesis of the Lower Extremity-Results from the Pilot Randomized Controlled Trial proGAIT. 41
36290890 2022
2
Development and Validation of Nomograms to Assess Risk Factors and Overall Survival Prediction for Lung Metastasis in Young Patients with Osteosarcoma: A SEER-Based Study. 41
36380749 2022
3
Observation of the Curative Effect of Acupuncture for Tonifying Kidney and Removing Blood Stasis Combined with Radiofrequency Surgery in Patients with NSCLC and the Diagnostic Efficacy of Combined Detection of NTx, BGP, and CYFRA21-1 in the Occurrence of Bone Metastases. 41
36247849 2022
4
Targeting the nitric oxide/cGMP signaling pathway to treat chronic pain. 62
36254980 2023
5
Frontal sinus giant osteoma with radiologically unusual component suggesting blood supply: A case report. 62
36457794 2023
6
A cost effective method for the preparation of sodium fluoride [18F]NaF for PET-CT imaging by using an in-house designed module. 62
36423501 2023
7
Efficacy of Trevesia palmata (Roxb. ex Lindl.) Vis. Extract on MG 63 cell lines and arthritis-induced animal models. 62
36152784 2023
8
The mitotic regulator polo-like kinase 1 as a potential therapeutic target for c-Myc-overexpressing canine osteosarcomas. 62
36054794 2022
9
Metformin: new applications for an old drug. 62
36474458 2022
10
Datasets for the reporting of primary tumour in bone: recommendations from the International Collaboration on Cancer Reporting (ICCR). 62
36464647 2022
11
Bone tumors effective therapy through functionalized hydrogels: current developments and future expectations. 62
35612368 2022
12
Response to: Prognosis of metastatic bone cancer and myeloma patients and long‑term risk of medication‑related osteonecrosis of the jaw (MRONJ): some critical points. 62
36318340 2022
13
Prognosis of metastatic bone cancer and myeloma patients and long-term risk of medication-related osteonecrosis of the jaw (MRONJ): some critical points. 62
35882670 2022
14
[223Ra] RaCl2 nanomicelles showed potent effect against osteosarcoma: targeted alpha therapy in the nanotechnology era. 62
35191342 2022
15
Expression of the hedgehog signalling pathway and the effect of inhibition at the level of smoothened in canine osteosarcoma cell lines. 62
35521940 2022
16
Reduction of breast cancer extravasation via vibration activated osteocyte regulation. 62
36419845 2022
17
Melatonin attenuates bone cancer pain via the SIRT1/HMGB1 pathway. 62
36122662 2022
18
New ternary Fe(III)-8-hydroxyquinoline-reduced Schiff base complexes as selective anticancer drug candidates. 62
36049258 2022
19
Activation of the STING pathway induces peripheral sensitization via neuroinflammation in a rat model of bone cancer pain. 62
36346430 2022
20
P2X7 Receptor-Induced Bone Cancer Pain by Regulating Microglial Activity via NLRP3/IL-1beta Signaling. 62
36375190 2022
21
Novel Application of 3D Scaffolds of Poly(E-Caprolactone)/Graphene as Osteoinductive Properties in Bone Defect. 62
36351454 2022
22
Cyclin D1 mediates pain behaviour in a rat model of breast cancer-induced bone pain by a mechanism involving regulation of the proliferation of spinal microglia. 62
36374014 2022
23
Parental occupational and environmental risk factors for childhood bone cancer in Mansoura oncology center: a case control study. 62
36372065 2022
24
Activation of HCN channels caused by elevated cAMP levels in periaqueductal gray promotes bone cancer pain. 62
36336089 2022
25
Basolateral Amygdala Reactive Microglia May Contribute to Synaptic Impairment and Depressive-Like Behavior in Mice with Bone Cancer Pain. 62
36002639 2022
26
Vascularized and Non-vascularized Fibula Grafts in Tumour Reconstruction: Single Centre Experience With Mid to Long-term Results. 62
36288889 2022
27
Rhizoma Paridis saponins suppresses vasculogenic mimicry formation and metastasis in osteosarcoma through regulating miR-520d-3p/MIG-7 axis. 62
36184123 2022
28
Long non-coding RNA MALAT1 promotes cell proliferation, migration and invasion by targeting miR-590-3p in osteosarcoma. 62
36277152 2022
29
Lipoyl-Based Antagonists of Transient Receptor Potential Cation A (TRPA1) Downregulate Osteosarcoma Cell Migration and Expression of Pro-Inflammatory Cytokines. 62
36407953 2022
30
Anti-GD2 antibody for radiopharmaceutical imaging of osteosarcoma. 62
35809088 2022
31
A meta-analysis comparing efficiency of limb-salvage surgery vs amputation on patients with osteosarcoma treated with neoadjuvant chemotherapy. 62
35122396 2022
32
Diffuse Bone Marrow Involvement of Multiple Myeloma on [ 18 F]PSMA-1007 PET/CT : Is There a Theranostic Potential? 62
35619194 2022
33
Medication-related osteonecrosis of the jaw: Prosthodontic considerations. 62
34984072 2022
34
Chondromyxoid fibroma of the iliac bone: a brief radiological review. 62
36446478 2022
35
Synchronous polyostotic solid variant of aneurysmal bone cyst involving thoracic vertebrae and harboring a novel AHNAK::USP6 gene fusion. A case report and review. 62
35717456 2022
36
In situ mass spectrometry imaging reveals heterogeneous glycogen stores in human normal and cancerous tissues. 62
36059248 2022
37
Extraskeletal Ewing's Sarcoma With Vertebral Metastasis: A Case Report. 62
36465784 2022
38
Predicting length of stay after proximal femoral endoprosthetic replacement for oncological conditions. 62
34446348 2022
39
Osteo-modulatory dietary proteins and peptides: A concise review. 62
35933727 2022
40
Differences in stromal component of chordoma are associated with contrast enhancement in MRI and differential gene expression in RNA sequencing. 62
36192442 2022
41
GRM1 Immunohistochemistry Distinguishes Chondromyxoid Fibroma From its Histologic Mimics. 62
35650682 2022
42
Upregulation of Nav1.6 Mediated by the p38 MAPK Pathway in the Dorsal Root Ganglia Contributes to Cancer-Induced Bone Pain in Rats. 62
36359772 2022
43
Cancer Inhibition and In Vivo Osteointegration and Compatibility of Gallium-Doped Bioactive Glasses for Osteosarcoma Applications. 62
36170227 2022
44
Engineering Novel 3D Models to Recreate High-Grade Osteosarcoma and its Immune and Extracellular Matrix Microenvironment. 62
36057996 2022
45
Circ-CTNNB1 drives aerobic glycolysis and osteosarcoma progression via m6A modification through interacting with RBM15. 62
36181462 2022
46
A comparison of osteoarticular allografts and allograft-prosthesis composites for reconstruction of the distal femur after resection of a bone tumour in childhood : a retrospective study. 62
36177642 2022
47
A concise review on implications of silver nanoparticles in bone tissue engineering. 62
36088719 2022
48
Overexpression of GDNF in Spinal Cord Attenuates Morphine Analgesic Tolerance in Rats with Bone Cancer Pain. 62
36138924 2022
49
Risk, Prognostic Factors and Nomograms for Bone Metastasis in Young Females with Breast Cancer: A Large Cohort Retrospective Study. 62
36074969 2022
50
Roles of Gut Microbiome in Bone Homeostasis and Its Relationship with Bone-Related Diseases. 62
36290306 2022
Sources

Variations for Bone Cancer

About this section

Copy number variations for Bone Cancer from CNVD:

6
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 70082 12 58138784 58142025 Amplification TSPAN31 Bone cancer
2 70083 12 58141509 58146230 Amplification CDK4 Bone cancer
3 71134 12 67700000 68661632 Amplification MDM2 Bone cancer
Sources

Expression for Bone Cancer

About this section
Search GEO for disease gene expression data for Bone Cancer.
Sources

Pathways for Bone Cancer

About this section

Pathways related to Bone Cancer according to GeneCards Suite gene sharing:

(show all 14)
# Super pathways Score Top Affiliating Genes
1
Colorectal Cancer Metastasis 64
11.78 TP53 MMP9 EGFR CASP3
2
DNA IR-double strand breaks and cellular response via ATM 74
Show member pathways
 11.68 TP53 CDKN2A CASP3
3
Cell differentiation - expanded index 74
Show member pathways
 11.55 MIR9-1 MIR199A1 MIR17
4
Spinal cord injury 74
11.52 TP53 MMP9 EGFR CASP3
5
Burn wound healing 74
11.51 TP53 MMP9 CASP3
6
Head and neck squamous cell carcinoma 74
11.47 TP53 EGFR CDKN2A
7
AP-1 transcription factor network 61
11.42 TP53 MMP9 CDKN2A
8
miRNAs involved in DNA damage response 74
11.37 MIR17 MIR21 TP53
9
LPA receptor mediated events 61
11.17 MMP9 EGFR CASP3
10
Transcription_Transcription factor Tubby signaling pathways 22
11.12 TP53 EGFR CASP3
11
miRNAs involvement in the immune response in sepsis 74
11.05 MIR9-1 MIR21 MIR199A1 MIR126
12
ERK pathway in Huntington's disease 74
10.71 EGFR CASP3
13
Bladder cancer 74
10.53 TP53 MMP9 EGFR CDKN2A
14
Mammary gland development pathway - Involution (Stage 4 of 4) 74
10.49 TP53 MMP9
Sources

GO Terms for Bone Cancer

About this section

Cellular components related to Bone Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.77 MMP9 MIR877 MIR485 MIR335 MIR21 MIR199A1
2 RISC complex GO:0016442 9.7 MIR9-1 MIR877 MIR876 MIR485 MIR433 MIR335

Biological processes related to Bone Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of apoptotic process GO:0043065 10.08 TP53 MMP9 MIR21 CDKN2A CASP3
2 positive regulation of vascular associated smooth muscle cell proliferation GO:1904707 9.73 MMP9 MIR21 MIR17
3 miRNA-mediated gene silencing GO:0035195 9.7 MIR9-1 MIR877 MIR876 MIR485 MIR433 MIR335
4 positive regulation of protein kinase B signaling GO:0051897 9.65 MIR21 MIR199A1 MIR126 EGFR
5 negative regulation of gene expression GO:0010629 9.63 MIR17 MIR183 MIR199A1 MIR21 MIR9-1 TP53
6 positive regulation of miRNA maturation GO:1903800 9.46 TP53 EGFR
7 positive regulation of cardiac muscle hypertrophy in response to stress GO:1903244 9.4 MIR199A1 MIR17
8 negative regulation of vascular associated smooth muscle cell apoptotic process GO:1905460 9.37 MIR21 MIR17
9 miRNA-mediated gene silencing by inhibition of translation GO:0035278 9.35 MIR9-1 MIR877 MIR21 MIR17 MIR126
10 positive regulation of metalloendopeptidase activity GO:1904685 9.32 MIR21 MIR17

Molecular functions related to Bone Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA 3'-UTR binding GO:0003730 9.7 TP53 MIR9-1 MIR335 MIR21 MIR199A1 MIR183
2 mRNA base-pairing translational repressor activity GO:1903231 9.44 MIR9-1 MIR877 MIR876 MIR485 MIR335 MIR32
Sources

Sources for Bone Cancer

About this section
2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....